ABSTRACT: Multi-target design offers access to bioactive small molecules with potentially superior efficacy and safety. Particularly multifactorial chronic inflammatory diseases demand multiple pharmacological interventions for stable treatment. By minor structural changes, we have developed a close analogue of the cysteinyl-leukotriene receptor antagonist zafirlukast that simultaneously inhibits soluble epoxide hydrolase and activates peroxisome proliferator-activated receptor γ. The triple modulator exhibits robust anti-inflammatory activity in vivo and highlights the therapeutic potential of designed multi-target agents.
INTRODUCTION
Though anti-inflammatory drug discovery is very intensive 1 , inflammatory diseases remain amongst the most serious health burdens and there is unmet medical need for more efficacious anti-inflammatory drugs. The number of drugged targets in inflammatory diseases is constantly growing but especially in the most severe, chronic disorders even innovative agents fail to produce sufficient therapeutic efficacy 1 . As a very complex pathophysiological process, inflammation involves a myriad of enzymes, mediators and receptors and pharmacological modulation of a single target tends to cause shunting effects that compromise therapeutic efficacy 2 . Thus, robust anti-inflammatory therapies often require the use of multiple drugs but considering the drawbacks of excessive polypharmacy, a multi-target antiinflammatory agent seems a superior approach.
RESULTS & DISCUSSION
To generate such multi-target anti-inflammatory agent, we selected the cysteinyl leukotriene receptor 1 (CysLT1R) 3, 4 antagonist zafirlukast (1) 5 for which we have observed moderate off-target activity (Table 1) on the peroxisome proliferator-activated receptor γ (PPARγ) 6 and the soluble epoxide hydrolase (sEH) 7 . Like CysLT1R, PPARγ and sEH interact with metabolites of arachidonic acid and hold great anti-inflammatory potential 1 and their selective modulation reduced acute inflammation in animal models 8, 9 . The weak side-activities of the fatty acid mimetic 10 1, therefore, seem supportive of an anti-inflammatory efficacy and we aimed to optimize the PPARγ agonistic and sEH inhibitory activity of 1 while retaining CysLT1R antagonism to generate a triple modulator that simultaneously addresses three anti-inflammatory targets.
To establish a strategy for structural optimization, we analyzed the putative binding mode of 1 in the PPARγ ligand binding domain (PDB-ID: 3WMH) and the sEH C-terminal domain (PDB-ID: 5ALZ 11 ) by molecular docking (Figure 1 , detailed view in Figures S1&S2) . Examination of the best scored poses suggested that minor changes would allow marked improvements in potency. Spatial extension of the urethane cyclopentyl substituent to a six-membered ring seemed favorable for PPARγ and sEH binding since the urethane O-substituent protruded into lipophilic sub-pockets of both targets which offered additional space for a larger ring. Moreover, caused by its ortho-methyl residue, the phenylsulfonamide obtained a dihedral conformation that was disfavored by PPARγ and might be resolved through a free ortho-position which was supported by strain energy calculations (Table S1 ). Interaction potential analysis in the phenylsulfonamide binding region in the PPARγ ligand binding site, furthermore, suggested opportunities for optimization in meta-or para-substitution of said ring with small halogens. And finally, replacement of the urethane moiety in 1 by urea appeared to optimize sEH inhibitory potency by adding a further H-bond donor that would enable an additional H-bond towards Asp335. Guided by these in silico observations, we prepared analogues of 1 with small but concerted structural changes to enhance triple potency.
Analogues 2-10 were prepared in an eight-step synthetic procedure adopted from a published 12 approach to 1 with suitable modifications (Scheme 1). In brief, N-methyl-5-nitroindole (11) was available from 12 by methylation with DMS. Esterification of 13 followed by radical bromination yielded building block 14 which was coupled with 11 to 15 under Friedel-Craft conditions using FeCl3 as catalyst. After reducing 15 with H2 and Pd(C) to aniline 16, urethane 17 was available from 16 and chloroformate 18 while reaction of 16 with isocyanates 19 and 20 produced ureas 21 and 22. Finally, ester hydrolysis in 17, 21 and 22 to free acids 23-25 followed by sulfonamide coupling with DCC/DMAP and 26-30 afforded 2-10 in 8-12% overall yield.
PPARγ agonistic potency of analogues 2-10 was quantified in a specific reporter gene assay 13 based on a hybrid receptor comprising the PPARγ-LBD and the DNA-binding domain of the nuclear receptor Gal4 from yeast. Inhibition of sEH was determined in a fluorescencebased assay 14 with recombinant protein and PHOME as fluorogenic substrate. A cellular leukotriene D4 induced Ca 2+ -influx assay in Cos-7 cells transiently overexpressing CysLT1R 15 served to characterize antagonistic potency of 2-10 on CysLT1R (Table 1) .
Based on our docking study, we replaced the urethane moiety of 1 by a urea (2) which expectedly was accompanied by a significant improvement in sEH inhibitory potency while CysLT1R antagonism dropped dramatically. On PPARγ, replacement of the urethane moiety by urea hardly affected the EC50 value but significantly diminished transactivation efficacy. Considering that weight gain is a common adverse effect of full PPARγ agonists and that partial agonists lack this undesired activity while retaining anti-inflammatory effects of PPARγ modulation [16] [17] [18] , partial agonistic activity on PPARγ appears favorable and safer.
Ring expansion from cyclopentylurea 2 to cyclohexylurea 3 further promoted sEH inhibition and markedly improved PPARγ agonism but was poorly tolerated concerning CysLT1R antagonism. Variations in the sulfonamide moiety were better tolerated by CysLT1R with unsubstituted phenylsulfonamide 4 and 3-chlorophenylsulfonamide 5 retaining a pA2 value above 10. As suggested by the proposed binding mode, the freely rotatable phenylsulfonamides 4 and 5 strongly enhanced PPARγ agonistic potency. Inhibitory potency on sEH was hardly affected by changes in the sulfonamide region. Thus, we combined cyclohexylurea (3) and 3-chlorophenylsulfonamide (5) as most favorable modifications for sEH inhibition and PPARγ agonistic potency, respectively. The resulting compound 6 comprised balanced triple modulatory potency on PPARγ, sEH and CysLT1R. Introduction of a second chlorine atom in 7 and replacement of chlorine by trifluoromethyl (8) failed to improve the triple activity while replacement of chlorine by fluorine (9) was slightly favored by PPARγ and sEH but not by CysLT1. Intriguingly, the most favorable triple activity profile was achieved with unsubstituted phenylsulfonamide 10. As assumed from the proposed binding poses, three minor structural changes were sufficient to generate a triple modulator with nanomolar potency on PPARγ, sEH and CysLT1R.
Off-target profiling of 1 and 10 on nuclear receptors (Figure S3A ) revealed significantly reduced off-target activity for the triple modulator 10 despite its designed polypharmacological profile while 1 turned out remarkably unselective. Especially its agonistic activity on pregnane X receptor (PXR) and constitutive androstane receptor (CAR) may compromise the safety of 1 since these xenobiotic receptors drive cytochrome P450 expression, promote drug metabolism and can be a basis of drug-drug interactions 19, 20 . In contrast to 1, the triple modulator 10 was inactive on CAR and only weakly activated PXR.
Moreover, the triple modulator 10 comprised remarkably higher aqueous solubility (10: 2.1 mg/L; 1: 0.14 mg/L) and a lower logD7.4 value (10: 1.70; 1: 2.47) than 1, and was considerably less toxic ( Figure S3B-D) . Microsomal stability was high for both, 10 and lead structure 1 with 65% and 73%, respectively, remaining after 4 hours incubation (Figure S1E) . Under cellular conditions, 10 robustly inhibited sEH product formation in HepG2 homogenates with an IC50 value of 14±2 nM and induced PPARγ target gene expression in HepG2 cells (Figure 2A/B) . However, in contrast to PPARγ agonist rosiglitazone, 10 did not induce adipocyte differentiation and failed to induce PPARγ regulated gene expression in this cell-type ( Figure 2C/D) . Thus, 10 comprises a non-adipogenic, selective PPARγ modulatory profile as it has been observed for other PPARγ ligands 18 .
Pilot in vivo evaluation of 10 in four wild-type male C57Bl6/J mice ( Figure 3A -C) revealed a favorable pharmacokinetic profile after oral application of 10 mg/kg 10 with rapid uptake, good bioavailability and a terminal half-life of 1.9 h resulting in effective concentrations for PPARγ activation over approx. 4 h. Sufficient concentrations of 10 for sEH inhibition and CysLT1R antagonism were still detectable after 8 h. The EET/DHET ratio was significantly shifted towards sEH substrates 8 h post dose and of expression PPARγ target gene CD36 was upregulated in mouse livers compared to vehicle treated animals. Encouraged by the favorable in vitro and pilot in vivo data, we studied anti-inflammatory activity of 10 in the model of paw edema induced by intraplantar injection of zymosan in mice, which closely mimics the symptoms of inflammation in man 21 ( Figure 3D ). 1 (10 mg/kg), 10 (10 mg/kg) or vehicle were administered orally 30 min prior to zymosan, and the paw edema was assessed by plethysmometry. 8 h after zymosan injection, the paw edema was indistinguishable between groups. 24 h after zymosan injection, the paw edema was significantly reduced in mice treated with 10 compared to vehicle-treated mice whereas 1 did not affect the extent of paw edema. Control experiments revealed no change in paw size in the contralateral hindpaw. These data confirm that 10 exerts anti-inflammatory effects in vivo and that triple target modulation of 10 is superior to 1.
PPARγ activation 9 , e.g. with the full agonist rosiglitazone, as well as sEH inhibition 8 have revealed some therapeutic efficacy in animal models of acute inflammation similar to the paw edema model used in our study. Designing PPARγ agonistic and sEH inhibitory activity into 1 provided the triple modulator 10 with significantly superior anti-inflammatory effects compared to 1 in a murine model of acute inflammation. Notably, 10 only exhibits partial PPARγ agonism which proved sufficient to achieve this anti-inflammatory activity underlining a great advantage of multi-target modulation. When supportive target combinations are addressed simultaneously, partial modulation of these targets can be sufficient to achieve the desired therapeutic effects which may allow the development of multi-target compounds with high efficacy and reduced adverse activity 2 .
The triple modulatory potency of 10 may be of therapeutic value in a variety of diseases involving inflammatory processes. Particularly, in allergic asthma for which 1 is approved, PPARγ plays a central role in the regulation of airway inflammation involving modulation of IL-17 production 22 and eosinophil differentiation 23 . Accordingly, PPARγ agonists showed therapeutic efficacy in animal models of allergic asthma including anti-inflammatory and bronchodilatory activity 22, 24, 25 . Even a correlation of PPARγ polymorphisms with asthma development has been reported 26 . Moreover, sEH inhibition reduced allergic airway inflammation and hyperresponsiveness in ovalbumin induced asthma in mice 27 suggesting that all three molecular targets of 10 are suitable to treat allergic asthma.
Beyond asthma, chronic obstructive pulmonary disease (COPD) may also markedly profit from PPARγ activation combined with inhibition of CysLT1R and sEH. Recent clinical observations have found decreased expression of PPARγ in lung tissue of COPD patients 28 and reduced COPD exacer- Figure 3 . In vivo pharmacological characterization of triple modulator 10: Pharmacokinetic profiling of 10 after a 10 mg/kg p.o. dose revealed rapid uptake, high bioavailability and a half-life of 2 h (A, results are mean±SEM; n=4). In healthy male wild-type C57BL6/J mice, 10 increased plasma sEH substrate/product ratio (B) and modulated hepatic transcription of PPARγ target gene CD36 (C, results are mean±SEM; n(vehicle)=2, n(10)=4). In the paw edema model in C57BL/6N mice pretreated with vehicle, 1 or 10 30 min prior to zymosan injection into one hindpaw (D), 10 significantly reduced paw edema after 24 h suggesting anti-inflammatory potency in vivo and was superior to lead compound 1 confirming increased efficacy through designed multi-target activity (solid lines -ipsilateral paw; dotted lines -contralateral paw; results are mean±SEM; n=6). * p < 0.05. bations in patients receiving PPARγ agonistic thiazolidinediones 29 . Moreover, treatment with CysLT1R antagonist 1 improved the lung function of COPD patients 30 and sEH inhibitors possessed therapeutic efficacy in COPD mouse models 31, 32 . The rational combination of simultaneously modulating these three biological targets with a single molecule may, therefore, produce superior therapeutic efficacy in COPD.
CONCLUSION
The development of triple modulator 10 and its activity profile compared to 1 highlight the remarkable impact of very minor structural changes on a drug's effects and efficacy. Concerted optimization of intrinsic off-target activities of 1 generated the potent triple modulator 10 which by modulating three individual anti-inflammatory targets comprises significantly enhanced anti-inflammatory potency in vivo while conserving the lead compound's structural properties, molecular weight and pharmacokinetic profile. This alternative interpretation of selective optimization of side-activities 33 might hold great potential for numerous drug molecules, especially in times of increasing polypharmacy.
EXPERIMENTAL
General. All final compounds (2-10) for biological evaluation had a purity of >95% according to HPLC-UV analysis at wavelengths 245 and 280 nm. 5-(3-Cyclohexylureido)-1-methyl-1H-indol-3-yl) methyl)-3-methoxy-N-(phenylsulfonyl)benzamide (10): 4-((5-(3-Cyclohexylureido)-1-methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24, 50 mg, 0.11 mmol, 1.00 eq) was dissolved in chloroform (abs., 10 mL) and benzenesulfonamide (26, 23 mg, 0.15 mmol, 1.30 eq), dicyclohexyl carbodiimide (35 mg, 0.17 mmol, 1.50 eq) and 4-(N,N-dimethylamino)pyridine (14 mg, 0.11 mmol, 1.00 eq) were added and the mixture was stirred under reflux for 12 h. After cooling to room temperature, 10 mL 5% aqueous hydrochloric acid were added, phases were separated, and the aqueous layer was extracted with EtOAc (3x10 mL). The combined organic layers were dried over Na2SO4 and the solvents were evaporated under reduced pressure. The crude product was purified by column chromatography using EtOAc/hexane/acetic acid (9:89:2) as mobile phase. The residue was then dissolved in 0.5 mL methanol, 10 mL water were added, and the suspension was immediately frozen and lyophilized to yield the title compound as colorless solid (50 mg, 76%). 1 28 g, 32. 0 mmol, 2.1 eq) was added and the mixture was stirred for 10 min at 40 °C. Dimethyl sulfate (1.68 mL, 17.7 mmol, 1.2 eq) was carefully added and the mixture was stirred for another 2 h at 40 °C. Then, H2O was added to precipitate the title compound as a yellow solid (6.12 g, 23%). 1 Methyl 3-methoxy-4-methylbenzoate (14a): 3-Methoxy-4-methylbenzoic acid (13, 5 .00 g, 30.1 mmol, 1.0 eq) was dissolved in MeOH (abs., 150 mL). Thionyl chloride (3.30 mL, 45.5 mmol, 1.5 eq) was carefully added, and the mixture was refluxed for 6 h. 50 mL 2 N aqueous hydrochloric acid were then added, and the mixture was extracted with CHCl3 (3x50 mL). The combined organic layers were dried over MgSO4 and the solvent was evaporated in vacuum to obtain the title compound as a colorless solid (4.26 g, 79%). 1 (15): 1-Methyl-5-nitro-1H-indole (11, 699 mg, 4.00 mmol, 1.0 eq) and methyl 4-(bromomethyl)-3-methoxybenzoate (14, 1.00 g, 4.00 mmol, 1.0 eq) were dissolved in 1,4-dioxane (abs., 50 mL), FeCl3 (1.94 g, 12.0 mmol, 3.0 eq) was carefully added, and the mixture was stirred at room temperature for 12 h. The mixture was then filtered through celite, the filtrate was dried over MgSO4, and the solvent was evaporated in vacuum. Further purification was performed by column chromatography using n-hexane/EtOAc (5:1) as mobile phase to obtain the title compound as yellow solid (0.53 g, 38%). 1 50 mmol, 1.0 eq) was dissolved in 10 mL EtOH and Pd(C) (53 mg, 0.05 mmol, 0.1 eq) was added. The suspension was stirred at room temperature under H2 atmosphere for 12 h. The mixture was then filtered through celite, the filtrate was dried over MgSO4, and the solvent was evaporated in vacuum to obtain the title compound as pale purple solid (0.15 g, 94%). 1 5-(3-cyclohexylureido)-1-methyl-1H-indol-3 yl)methyl)-3-methoxybenzoate (21): Methyl 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (16, 487 mg, 1.50 mmol, 1.00 eq) was dissolved in THF (abs., 22 mL) and DBU (abs., 0.75 mL) was added. Cyclohexylisocyanate (19, 281 mg, 2.25 mmol, 1.50 eq) was added dropwise and the mixture was stirred at 40°C for 12 h. 30 mL 1% aqueous hydrochloric acid were added and the mixture was stirred for another 5 minutes. After addition of 15 mL EtOAc phases were separated and the aqueous layer was extracted with EtOAc (2x30 mL). The combined organic layers were dried over Na2SO4 and the solvents were evaporated under reduced pressure. The crude product was purified by column chromatography using EtOAc/hexane (1:4) as mobile phase to yield the title compound as colorless solid (330 mg, 49%). 1 5-(3-Cyclohexylureido)-1-methyl-1H-indol-3-yl) methyl)-3-methoxybenzoic acid (24) : Methyl 4-((5-(3-cyclohexylureido)-1-methyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (21, 310 mg, 0.69 mmol, 1.00 eq) was dissolved in methanol (6 mL), water (12 mL) and lithium hydroxide (198 mg, 8.28 mmol, 12.0 eq) were added and the mixture was stirred at room temperature for 16 h. After acidification with 20 mL 10% aqueous hydrochloric acid, the mixture was extracted with EtOAc (3x25 mL). The combined organic layers were dried over Na2SO4 and the solvents were evaporated under reduced pressure. The crude product was purified by column chromatography using EtOAc/hexane/acetic acid (19:79:2) as mobile phase to yield the title compound as colorless solid (265 mg, 88%). 1 
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